BRPI1014995A2 - ligantes peptídeos para o isolamento e tratamento de células t autoimunes - Google Patents

ligantes peptídeos para o isolamento e tratamento de células t autoimunes

Info

Publication number
BRPI1014995A2
BRPI1014995A2 BRPI1014995A BRPI1014995A BRPI1014995A2 BR PI1014995 A2 BRPI1014995 A2 BR PI1014995A2 BR PI1014995 A BRPI1014995 A BR PI1014995A BR PI1014995 A BRPI1014995 A BR PI1014995A BR PI1014995 A2 BRPI1014995 A2 BR PI1014995A2
Authority
BR
Brazil
Prior art keywords
autoimmune
treatment
cell isolation
peptide ligands
ligands
Prior art date
Application number
BRPI1014995A
Other languages
English (en)
Inventor
Anne R Gocke
D Gomika Udugamasooriya
Thomas Kodadek
Original Assignee
Opko Health Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Health Inc, Univ Texas filed Critical Opko Health Inc
Publication of BRPI1014995A2 publication Critical patent/BRPI1014995A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
BRPI1014995A 2009-05-29 2010-05-28 ligantes peptídeos para o isolamento e tratamento de células t autoimunes BRPI1014995A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18236809P 2009-05-29 2009-05-29
US26060809P 2009-11-12 2009-11-12
PCT/US2010/036537 WO2010138797A1 (en) 2009-05-29 2010-05-28 Peptoid ligands for isolation and treatment of autoimmune t-cells

Publications (1)

Publication Number Publication Date
BRPI1014995A2 true BRPI1014995A2 (pt) 2016-04-26

Family

ID=42335126

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014995A BRPI1014995A2 (pt) 2009-05-29 2010-05-28 ligantes peptídeos para o isolamento e tratamento de células t autoimunes

Country Status (15)

Country Link
US (2) US20100303835A1 (pt)
EP (1) EP2435827A1 (pt)
JP (2) JP5991916B2 (pt)
KR (1) KR20120034683A (pt)
CN (1) CN102449481B (pt)
AU (1) AU2010253797B2 (pt)
BR (1) BRPI1014995A2 (pt)
CA (1) CA2763685A1 (pt)
CL (1) CL2011002959A1 (pt)
CO (1) CO6440595A2 (pt)
IL (1) IL216658A (pt)
MX (1) MX2011012680A (pt)
RU (1) RU2563822C2 (pt)
TW (1) TWI606238B (pt)
WO (1) WO2010138797A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764153C (en) 2009-06-02 2021-07-27 The Board Of Regents Of The University Of Texas System Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
JP2014504594A (ja) * 2011-01-10 2014-02-24 オプコ ファーマシューティカルズ、エルエルシー 自己免疫疾患における抗原代用物
JP6153921B2 (ja) 2011-03-24 2017-06-28 オプコ ファーマシューティカルズ、エルエルシー ビーズまたは粒子ベースのライブラリーを用いた液体生体試料中でのバイオマーカー発見、並びに診断キットおよび治療法
US9770504B2 (en) 2013-05-03 2017-09-26 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
EP3313866B1 (en) 2015-06-29 2024-11-20 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
US11053281B2 (en) 2016-03-09 2021-07-06 Mike-Ann, Llc Peptoid affinity ligands
WO2017165438A1 (en) 2016-03-25 2017-09-28 Muralidhar Reddy Moola Combinatorial synthesis and biomarker development
CN108588020B (zh) * 2018-03-30 2021-09-14 中国科学院苏州纳米技术与纳米仿生研究所 一种含有硒元素的近红外ii区量子点的新应用
CN110045105B (zh) * 2018-11-09 2022-04-26 广州市妇女儿童医疗中心 柯萨奇A16病毒IgA抗体量子点免疫荧光层析试纸条及试剂盒
EP4061146A4 (en) * 2019-07-03 2024-03-20 University of Houston System IL-15 INHIBITORS AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY CONDITIONS
US12343375B2 (en) 2021-02-09 2025-07-01 University Of Louisville Research Foundation, Inc. Spray dried formulation of a cholera toxin B subunit variant
CN113024643B (zh) * 2021-04-30 2022-05-13 武汉大学 一种人工拟肽及其制备方法和应用
WO2026032326A1 (zh) * 2024-08-06 2026-02-12 上海绾塍生物科技有限公司 一种目标细胞以及细胞表面受体的筛选方法
CN119290543B (zh) * 2024-12-13 2025-03-21 天津医科大学总医院空港医院 一种同时检测淋巴组织中il-6、il-21与t细胞cd4表面分子的试剂盒及方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011771A (en) * 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4789628A (en) * 1986-06-16 1988-12-06 Vxr, Inc. Devices for carrying out ligand/anti-ligand assays, methods of using such devices and diagnostic reagents and kits incorporating such devices
US5149626A (en) * 1987-05-14 1992-09-22 Mclean Hospital Corporation Multiple antigen immunoassay
CA2115333A1 (en) * 1993-02-16 1994-08-17 Shigeo Hozumi Polyfunctional vinyl ether compounds and photoresist resin composition containing the same
US5705614A (en) * 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
EP0700521B1 (en) * 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
ZA95605B (en) * 1994-04-28 1995-12-20 Qualcomm Inc Method and apparatus for automatic gain control and dc offset cancellation in quadrature receiver
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6083913A (en) * 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor
US20020022227A1 (en) * 1996-10-17 2002-02-21 Short Jay M. Morphatides: novel shape and structure libraries
US20020006620A1 (en) * 1996-10-17 2002-01-17 Invitrogen Corporation Morphatides: novel shape and structure libraries
WO1998027209A1 (en) * 1996-12-18 1998-06-25 Emory University Polycationic oligomers
US6365347B1 (en) * 1997-04-11 2002-04-02 The Regents Of The University Of California Method for identifying disruptors of biological pathways using genetic selection
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US6406632B1 (en) * 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
WO1999067640A1 (en) * 1998-06-22 1999-12-29 The Regents Of The University Of California Triggered optical biosensor
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6197599B1 (en) * 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US6306643B1 (en) * 1998-08-24 2001-10-23 Affymetrix, Inc. Methods of using an array of pooled probes in genetic analysis
US6465183B2 (en) * 1999-07-01 2002-10-15 Agilent Technologies, Inc. Multidentate arrays
GB9919452D0 (en) * 1999-08-17 1999-10-20 Osteometer Biotech As Specific autoimmune reactions against isomerised/optically inverted epitopes:application for diagnosis of autoimmune diseases
WO2001027624A2 (en) * 1999-10-08 2001-04-19 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
US6800728B2 (en) * 2000-03-22 2004-10-05 Solulink Biosciences, Inc. Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
AU2001259512B2 (en) * 2000-05-04 2007-03-01 Yale University High density protein arrays for screening of protein activity
WO2001092577A1 (en) * 2000-05-25 2001-12-06 Evorx Extracellular drug-oligonucleotides chimeric molecules
EP1287363A2 (en) * 2000-05-25 2003-03-05 Sunol Molecular Corporation Modulation of t-cell receptor interactions
EP1297338B1 (en) * 2000-06-05 2007-04-18 Novartis Vaccines and Diagnostics, Inc. Microarrays for performing proteomic analyses
US7153682B2 (en) * 2000-06-05 2006-12-26 Chiron Corporation Microarrays on mirrored substrates for performing proteomic analyses
CA2419490C (en) * 2000-08-15 2010-01-26 Discerna Limited Functional protein arrays
GB0022978D0 (en) * 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
EP1337667A2 (en) * 2000-11-16 2003-08-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
EP1343914A2 (en) * 2000-12-11 2003-09-17 HK Pharmaceuticals, Inc. Multiplexed protein expression and activity assay
US6800453B2 (en) * 2001-01-23 2004-10-05 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
US20020137106A1 (en) * 2001-03-09 2002-09-26 Ciphergen Biosystems, Inc. Detection of biological pathway components
AU2002256168B2 (en) * 2001-04-10 2007-09-20 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
WO2002084252A2 (en) * 2001-04-17 2002-10-24 Xenoport, Inc. Epitope-captured antibody display
EP1379545A2 (de) * 2001-04-19 2004-01-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
US6989276B2 (en) * 2001-05-10 2006-01-24 Battelle Energy Alliance, Llc Rapid classification of biological components
NO20013192L (no) * 2001-06-25 2002-12-27 Medinnova As Metode for monitering av T-celler
WO2003019192A1 (en) * 2001-08-27 2003-03-06 The Trustees Of Boston University Apparatus, composition and method for proteome profiling
US7504364B2 (en) * 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
NZ536420A (en) * 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
US7736909B2 (en) * 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
US7884052B2 (en) * 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
JP4864425B2 (ja) * 2005-03-18 2012-02-01 株式会社膠原病研究所 全身性エリテマトーデスの発症の判定のためのデータ取得方法およびその利用
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists

Also Published As

Publication number Publication date
KR20120034683A (ko) 2012-04-12
AU2010253797A1 (en) 2011-10-27
CL2011002959A1 (es) 2012-03-23
JP5991916B2 (ja) 2016-09-14
RU2563822C2 (ru) 2015-09-20
CN102449481B (zh) 2016-05-25
JP2012527904A (ja) 2012-11-12
CO6440595A2 (es) 2012-05-15
CA2763685A1 (en) 2010-12-02
CN102449481A (zh) 2012-05-09
JP2016185147A (ja) 2016-10-27
IL216658A (en) 2016-11-30
WO2010138797A1 (en) 2010-12-02
US20130178835A1 (en) 2013-07-11
AU2010253797B2 (en) 2015-03-12
TW201109658A (en) 2011-03-16
IL216658A0 (en) 2012-02-29
MX2011012680A (es) 2012-03-06
EP2435827A1 (en) 2012-04-04
TWI606238B (zh) 2017-11-21
US20100303835A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
BRPI1014995A2 (pt) ligantes peptídeos para o isolamento e tratamento de células t autoimunes
HRP20180616T1 (hr) Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba
PL3756657T3 (pl) Preparaty peptydu n-końcowego aneksyny a1 i sposoby
IL230918A0 (en) Modified proteins and peptides
DK3591046T3 (da) Amylasepolypeptide
BR112013008738A2 (pt) processos para purificação de proteínas
IL218753A0 (en) Protein arrays and uses thereof
BRPI1007295A8 (pt) peptídeos antibióticos
IL222027A (en) Peptides and their use
PT3151354T (pt) Alojamento e dispositivo de selagem
DK2498990T3 (da) Ensilagetildækning
PT2464370T (pt) Péptidos vasoativos intestinais modificados
DE112010003209A5 (de) Sitzfunktionsbezug
GB201012603D0 (en) Protein purification
EP2565200A4 (en) ANTIFREEZE PROTEIN
BRPI1008795A2 (pt) processos de alquilação e de hidroconversão
ME02224B (me) Antikancerski fuzioni protein
BRPI1010661A2 (pt) peptídeo
FI20095396A0 (fi) Alus
PL2627668T3 (pl) Peptydy i ich zastosowanie
BR112012023507A2 (pt) unidade de comutação e método relacionado
EP2762149A4 (en) PEPTIDE DERIVED FROM ERYTHROPOIETIN AND USE THEREOF
ZA201109283B (en) Protein
BR112013009679A2 (pt) peptídeo
BRPI1011474A2 (pt) peptideos antagonisticos para frizzled-1 e frizzled-2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 7/06 (2006.01), A61K 49/00 (2006.0

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.